Literature DB >> 17560117

Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy.

Andrea Huwiler1, Uwe Zangemeister-Wittke.   

Abstract

Sphingolipids not only function as structural components of cell membranes but also act as signaling molecules to regulate fundamental cellular responses, such as cell death and differentiation, proliferation and certain types of inflammation. Particularly the cellular balance between ceramide and sphingosine 1-phosphate seems to be crucial for a cell's decision to either undergo apoptosis or proliferate, two events which are implicated in tumor development and growth. Whereas ceramide possesses proapoptotic capacity in many cell types, sphingosine 1-phosphate acts as a counterplayer able to induce cell proliferation and protect cells from undergoing apoptosis. Therefore, tipping the balance in favour of ceramide production, i.e. by inhibiting ceramidase or sphingosine kinase activities has potential to support its proapoptotic action and hence represents a promising rational approach to effective cancer therapy. This review highlights most recent data on the regulation of cellular sphingolipid formation and their potential implication in tumor development, and provides perspectives for their use as targets in molecular intervention therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17560117     DOI: 10.1016/j.critrevonc.2007.04.010

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  26 in total

Review 1.  Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials.

Authors:  Thomas H Beckham; Saeed Elojeimy; Joseph C Cheng; Lorianne S Turner; Stanley R Hoffman; James S Norris; Xiang Liu
Journal:  Expert Opin Ther Targets       Date:  2010-05       Impact factor: 6.902

2.  The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo.

Authors:  Lu Dai; Charles D Smith; Maryam Foroozesh; Lucio Miele; Zhiqiang Qin
Journal:  Int J Cancer       Date:  2018-01-04       Impact factor: 7.396

3.  De Novo Fatty Acid Synthesis-Driven Sphingolipid Metabolism Promotes Metastatic Potential of Colorectal Cancer.

Authors:  Naser Jafari; James Drury; Andrew J Morris; Fredrick O Onono; Payton D Stevens; Tianyan Gao; Jinpeng Liu; Chi Wang; Eun Y Lee; Heidi L Weiss; B Mark Evers; Yekaterina Y Zaytseva
Journal:  Mol Cancer Res       Date:  2018-08-28       Impact factor: 5.852

4.  The ceramide kinase inhibitor NVP-231 inhibits breast and lung cancer cell proliferation by inducing M phase arrest and subsequent cell death.

Authors:  Oleksandr Pastukhov; Stephanie Schwalm; Uwe Zangemeister-Wittke; Doriano Fabbro; Frederic Bornancin; Lukasz Japtok; Burkhard Kleuser; Josef Pfeilschifter; Andrea Huwiler
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

5.  Improved synthesis of a fluorogenic ceramidase substrate.

Authors:  Zuping Xia; Jeremiah M Draper; Charles D Smith
Journal:  Bioorg Med Chem       Date:  2010-01-06       Impact factor: 3.641

6.  Ceramide signaling in cancer and stem cells.

Authors:  Erhard Bieberich
Journal:  Future Lipidol       Date:  2008-06

7.  Potent inhibition of Acid ceramidase by novel B-13 analogues.

Authors:  Denny Proksch; Jan Jasper Klein; Christoph Arenz
Journal:  J Lipids       Date:  2010-12-09

8.  Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases.

Authors:  Calogera M Simonaro; Marina D'Angelo; Xingxuan He; Efrat Eliyahu; Nataly Shtraizent; Mark E Haskins; Edward H Schuchman
Journal:  Am J Pathol       Date:  2007-12-13       Impact factor: 4.307

9.  Ceramide synthase 1 is regulated by proteasomal mediated turnover.

Authors:  Priya Sridevi; Hannah Alexander; Elad L Laviad; Yael Pewzner-Jung; Mark Hannink; Anthony H Futerman; Stephen Alexander
Journal:  Biochim Biophys Acta       Date:  2009-04-22

10.  Molecular signature of cell cycle exit induced in human T lymphoblasts by IL-2 withdrawal.

Authors:  Magdalena Chechlinska; Jan Konrad Siwicki; Monika Gos; Malgorzata Oczko-Wojciechowska; Michal Jarzab; Aleksandra Pfeifer; Barbara Jarzab; Jan Steffen
Journal:  BMC Genomics       Date:  2009-06-08       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.